Inari Medical (NARI) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2023Income Metrics
Revenue
493.6M
Gross Profit
434.6M
88.03%
Operating Income
-14.0M
-2.84%
Net Income
-1.6M
-0.33%
EPS (Diluted)
-$0.03
Balance Sheet Metrics
Total Assets
674.2M
Total Liabilities
209.3M
Shareholders Equity
464.9M
Debt to Equity
0.45
Cash Flow Metrics
Revenue & Profitability Trend
Inari Medical Income Statement From 2019 to 2023
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 493.6M | 383.5M | 277.0M | 139.7M | 51.1M |
| Cost of Goods Sold | 59.1M | 44.5M | 24.8M | 13.1M | 5.9M |
| Gross Profit | 434.6M | 339.0M | 252.2M | 126.6M | 45.2M |
| Operating Expenses | 448.6M | 367.1M | 241.4M | 108.1M | 44.4M |
| Operating Income | -14.0M | -28.1M | 10.8M | 18.4M | 801.0K |
| Pre-tax Income | 4.2M | -26.2M | 10.7M | 13.8M | -1.2M |
| Income Tax | 5.9M | 3.1M | 845.0K | 0 | 0 |
| Net Income | -1.6M | -29.3M | 9.8M | 13.8M | -1.2M |
| EPS (Diluted) | -$0.03 | -$0.55 | $0.18 | $0.27 | -$0.03 |
Income Statement Trend
Inari Medical Balance Sheet From 2019 to 2023
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 235.6M | 422.9M | 245.2M | 205.7M | 39.4M |
| Non-Current Assets | 438.7M | 81.2M | 66.3M | 8.4M | 5.1M |
| Total Assets | 674.2M | 504.2M | 311.5M | 214.1M | 44.5M |
| Liabilities | |||||
| Current Liabilities | 76.3M | 56.2M | 42.5M | 13.8M | 8.9M |
| Non-Current Liabilities | 133.0M | 31.0M | 29.8M | 0 | 74.8M |
| Total Liabilities | 209.3M | 87.2M | 72.3M | 13.8M | 83.7M |
| Equity | |||||
| Total Shareholders Equity | 464.9M | 417.0M | 239.2M | 200.3M | -39.1M |
Balance Sheet Composition
Inari Medical Cash Flow Statement
No cash flow data available.
Inari Medical Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-2,665.67
Forward P/E
571.21
Price to Book
10.75
Price to Sales
8.15
PEG Ratio
571.21
Profitability Ratios
Profit Margin
-13.68%
Operating Margin
-4.34%
Return on Equity
-17.72%
Return on Assets
-3.21%
Financial Health
Current Ratio
1.77
Debt to Equity
7.53
Beta
1.03
Per Share Data
EPS (TTM)
-$1.35
Book Value per Share
$7.44
Revenue per Share
$9.90
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| nari | 4.7B | -2,665.67 | 10.75 | -17.72% | -13.68% | 7.53 |
| Abbott Laboratories | 231.9B | 17.31 | 4.75 | 30.65% | 31.89% | 27.09 |
| Boston Scientific | 149.9B | 73.94 | 6.75 | 9.50% | 11.58% | 52.16 |
| Masimo | 9.1B | 129.16 | 9.63 | -25.07% | -23.25% | 72.01 |
| Globus Medical | 7.8B | 43.14 | 1.91 | 4.63% | 7.39% | 2.27 |
| Bio-Rad | 6.8B | -3.83 | 1.03 | -27.52% | -85.16% | 20.50 |
Financial data is updated regularly. All figures are in the company's reporting currency.